NCT03536663View on ClinicalTrials.gov

Clinical Study to Assess the Performance of the Dialyzer With Endexo™

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

April 17, 2019

Study Completion Date

June 17, 2019

Conditions
Kidney Failure, Chronic
Interventions
DEVICE

Optiflux and Dialyzer with Endexo

Hemodialysis (HD) on Optiflux dialyzer from Visit 1 to 12 and followed by HD on the dialyzer with Endexo at visit 13 and continues until visit 50. Dialysis is performed 3 times per week which means the total of the intervention will be 17 weeks.

Trial Locations (3)

67214

Research Management Inc/ Kansas Nephrology Research Institute, LLC-J/V, Wichita

92111

California Institute of Renal Research, San Diego

92154

Balboa Nephrology Med Group, Chula Vista

All Listed Sponsors
lead

Fresenius Medical Care North America

INDUSTRY

NCT03536663 - Clinical Study to Assess the Performance of the Dialyzer With Endexo™ | Biotech Hunter | Biotech Hunter